Cobra Biologics and Vaccibody Sign Agreement to Manufacture DNA Vaccine
News May 14, 2013
Cobra Biologics will apply its cost-effective platform process to deliver a programme of host strain generation, GMP cell banking, plasmid DNA production and clinical trials supply.
Vaccibody’s technology exploits the interplay between tissue, antigen presenting cells (APC), T-cells and B-cells to develop targeted vaccines designed to induce stronger and longer lasting immune responses than traditional vaccines. The platform technology allows for the tailored development of not only enhanced prophylactic vaccines but also therapeutic vaccines against chronic infections and cancers.
Peter Coleman CEO of Cobra Biologics said “Cobra has been manufacturing plasmid therapeutics and DNA vaccines for more than 14 years and I am delighted that we are able to announce the partnership with Vaccibody. Our DNA platform process is based on Cobra’s pioneering heritage in gene therapy manufacturing and technology development that we have successfully used for over 30 customers”.
Ole Henrik Brekke, CEO of Vaccibody said “With the significantly effective preclinical results VB 10.16 has shown, we are delighted now to take the next step towards clinical trials with Cobra Biologics as our manufacturing partner.”
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
British Pharmacological Society’s Drug Discovery of the Year 2018 AnnouncedNews
A new medicine used to treat an ultra-rare inherited disorder which leaves babies without a fully functioning immune system has been named the British Pharmacological Society’s Drug Discovery of the Year 2018.READ MORE